Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

177.06USD
17 Jul 2019
Change (% chg)

-- (--)
Prev Close
$177.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,141,586
52-wk High
$210.18
52-wk Low
$166.30

Select another date:

Thu, Jul 11 2019

BRIEF-Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With Bace Inhibitor Cnp520 For Alzheimer's Prevention

* AMGEN, NOVARTIS AND BANNER ALZHEIMER'S INSTITUTE DISCONTINUE CLINICAL RESEARCH PROGRAM WITH BACE INHIBITOR CNP520 FOR ALZHEIMER'S PREVENTION

BRIEF-Novartis, Amgen And Banner Alzheimer's Institute Discontinue Clinical Program With Bace Inhibitor CNP520

* CO, AMGEN AND BANNER ALZHEIMER'S INSTITUTE DISCONTINUE CLINICAL PROGRAM WITH BACE INHIBITOR CNP520 FOR ALZHEIMER'S PREVENTION Source text for Eikon: Further company coverage:

BRIEF-Amgen Wins FDA Approval For Kanjinti Injection For Treatment Of Breast Cancer, Gastroesophageal Junction Adenocarcinoma - FDA

* AMGEN WINS FDA APPROVAL FOR KANJINTI INJECTION FOR TREATMENT OF BREAST CANCER, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA - FDA WEBSITE

Amgen drug shows high response rate in small lung and colon cancer trial

An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday, sending the U.S. biotechnology company's share up nearly 6 percent.

UPDATE 1-Amgen drug shows high response rate in small lung and colon cancer trial

June 3 An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday, sending the U.S. biotechnology company's share up nearly 6 percent.

Amgen drug shows high response rate in small lung and colon cancer trial

June 3 An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday.

Amgen to buy Copenhagen-based Nuevolution for $167 million

Amgen, the world's largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery.

UPDATE 1-Amgen to buy Copenhagen-based Nuevolution for $167 mln

May 22 Amgen, the world's largest biotechnology company, agreed on Wednesday to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery.

Amgen offers to buy Copenhagen-based Nuevolution for $167 mln

May 22 Amgen, the world's largest biotechnology company, said on Wednesday it offered to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million).

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

INDIANAPOLIS Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients.

Select another date: